• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Piper Sandler initiated coverage on BridgeBio Pharma with a new price target

    9/4/24 7:30:16 AM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BBIO alert in real time by email
    Piper Sandler initiated coverage of BridgeBio Pharma with a rating of Overweight and set a new price target of $46.00
    Get the next $BBIO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BBIO

    DatePrice TargetRatingAnalyst
    6/17/2025$49.00Outperform
    Wolfe Research
    3/31/2025$50.00Buy
    Redburn Atlantic
    10/16/2024Sector Outperform
    Scotiabank
    10/3/2024Perform
    Oppenheimer
    9/4/2024$46.00Overweight
    Piper Sandler
    3/21/2024$45.00Outperform
    Raymond James
    1/31/2024$37.00Market Perform
    BMO Capital Markets
    12/8/2023$58.00Overweight
    Wells Fargo
    More analyst ratings

    $BBIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Wolfe Research initiated coverage on BridgeBio Pharma with a new price target

      Wolfe Research initiated coverage of BridgeBio Pharma with a rating of Outperform and set a new price target of $49.00

      6/17/25 7:49:06 AM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Redburn Atlantic initiated coverage on BridgeBio Pharma with a new price target

      Redburn Atlantic initiated coverage of BridgeBio Pharma with a rating of Buy and set a new price target of $50.00

      3/31/25 8:12:33 AM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Scotiabank initiated coverage on BridgeBio Pharma

      Scotiabank initiated coverage of BridgeBio Pharma with a rating of Sector Outperform

      10/16/24 8:38:45 AM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BBIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Director Valantine Hannah bought $24,948 worth of shares (1,752 units at $14.24), increasing direct ownership by 114% to 3,294 units (SEC Form 4)

      4/A - BridgeBio Pharma, Inc. (0001743881) (Issuer)

      6/30/25 5:49:25 PM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: Director Valantine Hannah bought $30,028 worth of shares (2,338 units at $12.84) (SEC Form 4)

      4/A - BridgeBio Pharma, Inc. (0001743881) (Issuer)

      6/30/25 5:46:18 PM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Valantine Hannah bought $44,476 worth of shares (3,433 units at $12.96) (SEC Form 4)

      4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)

      2/13/24 4:00:10 PM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care